三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

已收盘 06-26 16:08:11

15.910

-0.150

-0.93%

最高16.740	最低15.800	成交量2,542万
今开16.280	昨收16.060	日振幅5.85%
总市值403.64亿	流通市值403.64亿	总股本25.37亿
成交额4.08亿	换手率1.00%	流通股本25.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":15.91,"timestamp":1782461291004,"preClose":16.06,"halted":0,"volume":25420952,"delay":0,"changeRate":-0.009339975093399663,"floatShares":2537000000,"shares":2537000000,"eps":3.953945216007026,"marketStatus":"已收盘","change":-0.15,"latestTime":"06-26 16:08:11","open":16.28,"high":16.74,"low":15.8,"amount":408010897,"amplitude":0.058531,"askPrice":15.91,"askSize":43000,"bidPrice":15.89,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":3.953945216007026,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":16.06,"dividendRate":0.015713,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":0.802919,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2646780886","title":"三生制药(01530.HK)6月25日斥资约5537.52万港元回购346.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646780886","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646780886?lang=zh_cn&edition=full","pubTime":"2026-06-25 20:29","pubTimestamp":1782390552,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","BK1593","BK1583","01530","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646871804","title":"三生制药：8月4日将派发股息0.25港元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871804","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646871804?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:08","pubTimestamp":1782382080,"startTime":"0","endTime":"0","summary":"南财智讯6月25日电，三生制药（01530.HK）公告，公司于2026年6月25日召开的股东周年大会上，审议通过了截至2025年12月31日止年度末期股息分配方案，拟向登记在册股东派发末期股息每股普通股25港仙（即0.25港元）。股权登记日为2026年7月27日，预计派息日为2026年8月4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253783197234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1593","BK4585","VIG","BK4588","EWH","BK1583","HK0000165453.HKD","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879787","title":"三生制药(01530.HK)：毕马威获委任为新任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646879787?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:04","pubTimestamp":1782381871,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","01530","BK1161","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132275020","title":"异动解读｜三生制药盘中上涨5.23%，招银国际重点推荐叠加公司回购及板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1132275020","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132275020?lang=zh_cn&edition=full","pubTime":"2026-06-24 09:54","pubTimestamp":1782266073,"startTime":"0","endTime":"0","summary":"6月24日，三生制药盘中上涨5.23%，报17.27港元/股，成交额1.59亿港元。消息面上，多重利好共振推动股价走强。招银国际6月23日发布研报指出，中国医药行业正再现底部机会，创新药出海长期趋势不变，产业资本掀起回购及增持热潮释放底部信号，重点推荐三生制药等标的。同日，公司公告于6月22日斥资1571.80万港元回购101.3万股，回购价格区间为每股15.40至16.01港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004286","title":"创新药概念集体上涨，恒瑞医药、三生制药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004286","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645004286?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:40","pubTimestamp":1782182400,"startTime":"0","endTime":"0","summary":"6月23日，港股创新药概念股集体上涨，其中，华昊中天医药、石四药集团涨超7%，康诺亚-B涨超5%，恒瑞医药、科伦博泰生物、康方生物、三生制药、晶泰控股涨超4%，歌礼制药-B、再鼎医药、信达生物、亚盛医药、乐普生物、百济神州、药明生物涨超3%。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n            责任编辑：栎树","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2026/06/cms_20260623104000424.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/06/cms_20260623104000424.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/23104057544995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0405327494.USD","BK0060","LU1255011170.USD","BK0196","LU1997245094.SGD","LU2488822045.USD","LU2543165471.USD","LU2097828714.EUR","LU2097828557.USD","LU2495084118.USD","LU2580892789.USD","BK0028","LU2097828474.EUR","BK0012","LU0359201612.USD","LU1023057109.AUD","06978","LU1997245177.USD","01276","BK1593","BK0188","LU2328871848.SGD","LU2289578879.USD","LU1328615791.USD","LU1820825898.SGD","BK1583","BK0239","LU0359201885.HKD","01530","LU0405327148.USD","LU1655091616.SGD","LU2148510915.USD","LU1146622755.USD","159992","HK0000165453.HKD","LU1997244956.HKD","LU2097828631.EUR","LU1064131003.USD","BK0183","LU2097828805.USD","BK1161","LU2580892862.HKD","LU0359202008.SGD","LU1781817850.SGD","LU1969619763.USD","BK1191","LU1580142542.USD","BK1574","LU1064130708.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645402253","title":"三生制药(01530)6月22日斥资1571.8万港元回购101.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645402253","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645402253?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:22","pubTimestamp":1782130971,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年6月22日斥资1571.8万港元回购101.3万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01530","HK0000165453.HKD","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187574435","title":"三生制药6月22日回购101.3万股，涉资约1,571.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187574435","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187574435?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:21","pubTimestamp":1782130919,"startTime":"0","endTime":"0","summary":"三生制药(01530)于2026年6月22日公告称，公司当日于香港联交所场内回购普通股1,013,000股，占该公司当日已发行股本约0.04%。本次回购价格区间为每股15.40港元至16.01港元，总金额约1,571.80万港元。\n回购完成后，公司持有库藏股1,013,000股，已发行股本（不包括库藏股）降至2,537,071,412股，授权购回股份的总数为239,958,141股，该授权由公司于2025年6月25日获股东大会批准。公司确认，本次回购行为符合香港联交所上市规则及相关法律法规。\n本公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三生制药6月22日回购101.3万股，涉资约1,571.80万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124542422","title":"异动解读｜三生制药盘中上涨5.04%，生物科技板块集体反弹叠加机构连续增持提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1124542422","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124542422?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:27","pubTimestamp":1781749674,"startTime":"0","endTime":"0","summary":"6月18日，三生制药盘中上涨5.04%，报16.88港元/股，成交额1.45亿港元。消息面上，生物科技板块集体走强，康方生物涨6.97%、科伦博泰生物涨5.16%、荣昌生物涨4.97%、百济神州涨4.83%，板块呈现明显反弹态势。此前6月16日该板块曾集体承压下挫，本次反弹修复意味明显。此外，近期三生制药获多方增持支撑：汇添富基金于6月10日增持63.65万股、6月5日增持97.5万股；公司董事长娄竞于6月8日以每股15.25港元增持51.6万股，机构与管理层连续买入为市场信心提供支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644773208","title":"【券商聚焦】中信建投：生物制品板块跟随医药行业整体回调 考虑与资金因素有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2644773208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644773208?lang=zh_cn&edition=full","pubTime":"2026-06-18 09:26","pubTimestamp":1781745972,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究认为：1）中药：板块本周跑赢大盘及医药指数。市场关注呼吸道疾病发病率、基药目录等进展；除此市场持续关注“四同药品”价格专项治理、中成药集采等外部政策环境变化等带来的影响。2）生物制品：板块本周跑输医药指数及大盘。本周板块跟随医药行业整体回调，考虑主要与资金因素有关。3）医药商业：板块本周跑输申万医药，跑赢大盘。药店板块主要关注5月同店数据；流通板块关注院内合规及红利标的。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984059","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","IE00BPRC5H50.USD","LU0348767384.USD","BK1207","LU0348784397.USD","01789","LU1770034418.SGD","LU1719994722.HKD","SG9999004311.SGD","BK1100","06821","LU0348827113.USD","01530","BK1574","BK1197","IE00B3M56506.USD","09688","01099","LU0417516571.SGD","02196","LU0588546209.SGD","BK1161","BK1515","LU0640798160.USD","03933","LU1720050803.USD","LU0417516902.SGD","LU0540923850.HKD","LU0348735423.USD","02228","601066","BK1500","LU0348783233.USD","LU1969619763.USD","LU2476274308.USD","LU2328871848.SGD","SG9999014674.SGD","06160","BK1588","IE00B5MMRT66.SGD","BK1141","LU0561508036.HKD","LU2476274720.SGD","LU2399975544.HKD","BK1585","BK1191","LU1303224171.USD","LU0348766576.USD","02367","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643093780","title":"医美概念股普跌 三生制药(01530)下挫5.67% 机构指市场逐步由流量竞争转向品牌竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2643093780","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643093780?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:25","pubTimestamp":1781576726,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股普跌，截至发稿，三生制药(01530)跌5.67%，四环医药(00460)跌4.30%，巨子生物(02367)跌2.06%，复锐医疗科技(01696)跌1.98%，山东新华制药股份(00719)跌1.91%，昊海生物科技(06826)跌1.90%。消息面上，华龙证券表示，行业层面，医美市场逐步由流量竞争转向品牌竞争，精细化运营及长期用户管理成为机构提升竞争力的重要方向。产品层面，胶原蛋白注射产品商业化落地持续推进，行业发展重心正由传统填充向组织修复、皮肤质量改善及长期抗衰升级。长期来看，具备核心研发能力及品牌运营优势的企业有望持续受益于行业高质量发展趋势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","BK1583","00460","BK1207","BK1161","01530","SG9999004311.SGD","BK1600","BK1593","02367","00719","06826","BK1191","01696","BK1515","LU2488822045.USD","BK1100","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157065199","title":"异动解读｜三生制药盘中下跌5.79%，生物科技板块集体承压叠加沽空比例走高","url":"https://stock-news.laohu8.com/highlight/detail?id=1157065199","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157065199?lang=zh_cn&edition=full","pubTime":"2026-06-16 10:00","pubTimestamp":1781575218,"startTime":"0","endTime":"0","summary":"6月16日，三生制药盘中下跌5.79%，报16.11港元/股，成交额1.17亿港元。生物科技板块整体走弱，康方生物跌5.88%、荣昌生物跌4.57%、科伦博泰生物跌2.15%，板块集体承压。此外，近期三生制药沽空金额占成交比例一度升至18.74%，空方力量较为活跃。此前公司董事长于6月8日以每股15.25港元增持51.6万股，汇添富基金于6月10日增持63.65万股，但在板块系统性回调背景下个股仍受拖累。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","LU1960683339.HKD","02268","HK0000320264.USD","BK1576","01177","LU0348827113.USD","LU0051755006.USD","09966","01093","LU2097828631.EUR","01801","01530","LU0320764599.SGD","06990","09926","LU0456827905.SGD","LU0502904849.HKD","06996","01952","02269","LU0819121731.USD","03692","03759","06160","LU2399975544.HKD","09996","IE00BZ08YR35.GBP","LU0140636845.USD","03329","06078","01951","LU0737861772.HKD","LU1242518857.USD","02596","SG9999002562.SGD","BK1191","LU1688375341.USD","06821","HK0000306685.HKD","01548","LU1880383366.USD","02096","02273","IE00B0JY6N72.USD","LU0181495838.USD","01276","LU1226287875.USD","02162","LU3063872942.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228694","title":"三生制药获汇添富基金增持63.65万股 每股作价约16.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228694","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643228694?lang=zh_cn&edition=full","pubTime":"2026-06-15 07:17","pubTimestamp":1781479020,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，6月10日，汇添富基金管理股份有限公司增持三生制药（01530）63.65万股，每股作价16.2753港元，总金额约为1035.92万港元。增持后最新持股数目约为1.78亿股，持股比例为7%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-15/doc-inicmsvf5184093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","BK1593","HK0000165453.HKD","BK1161","01530","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642933772","title":"汇添富基金管理股份有限公司增持三生制药(01530)63.65万股 每股作价约16.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642933772","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642933772?lang=zh_cn&edition=full","pubTime":"2026-06-12 19:58","pubTimestamp":1781265489,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为1.78亿股，持股比例为7%。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260612/20260612195838_56755.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260612/20260612195838_56755.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1593","HK0000165453.HKD","EWH","01530","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642410609","title":"三生制药午后涨逾6% 获董事长增持涉资约786.88万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642410609","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642410609?lang=zh_cn&edition=full","pubTime":"2026-06-10 13:51","pubTimestamp":1781070660,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　三生制药（01530）盘中涨超7%，截至发稿，股价上涨5.97%，现报16.33港元，成交额5.78亿港元。\n　　香港联交所最新数据显示，6月8日，董事长兼首席执行官娄竞增持三生制药51.6万股，每股作价15.2497港元，总金额约为786.88万港元。增持后最新持股数目约为5.34亿股，最新持股比例为21.03%。中邮证券此前指出，公司坐拥特比澳等多个现金牛品种，为研发创新输入动力。707授权已落地，增厚公司利润的同时降低了在全球市场拓展的风险敞口。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-06-10/doc-iniawxzs6005122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","01530","BK1583","BK1161","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182727729","title":"异动解读｜三生制药盘中上涨5.32%，董事长增持叠加医保目录调整利好提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1182727729","media":"行情直击","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182727729?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:25","pubTimestamp":1781061957,"startTime":"0","endTime":"0","summary":"6月10日，三生制药盘中上涨5.32%，报16.23港元/股，成交额2.88亿港元。此前股价曾触及52周新低15.50港元，董事长在低位增持对市场情绪形成提振。同时，新一轮国家医保目录调整工作全面启动，公司此前凭借PD-1/VEGF双抗SSGJ-707与辉瑞达成15亿美元前端付款的出海授权合作，创新药管线价值获市场重新关注。此外，公司已授权董事可购回不超过已发行股本10%的股份，为股价提供进一步支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642984434","title":"董事长兼首席执行官娄竞增持三生制药(01530)51.6万股 每股作价15.2497港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2642984434","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642984434?lang=zh_cn&edition=full","pubTime":"2026-06-09 21:21","pubTimestamp":1781011269,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月8日，董事长兼首席执行官娄竞增持三生制药(01530)51.6万股，每股作价15.2497港元，总金额约为786.88万港元。增持后最新持股数目约为5.34亿股，最新持股比例为21.03%。补充资料：Dr. Lou Jing is an enforcer and a beneficiary of an unnamed discretionary trust.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HK0000165453.HKD","BK1161","01530","BK1593","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641101540","title":"港股异动 | 创新药概念股全线承压 流动性收紧直接压制板块估值 机构指BINSA草案影响偏情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=2641101540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641101540?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:08","pubTimestamp":1780902518,"startTime":"0","endTime":"0","summary":"消息面上，中东紧张局势推高能源价格之际，劳动力市场表现强劲，强化了市场对美联储年内加息的押注。国海证券此前在风险提示中指出，若全球及国内宏观货币政策节奏不及预期，将直接影响医药板块的估值水平与投融资环境。创新药、CXO等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。此外，6月2日，美国《生物技术投资国家安全法》法案公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","LU0880133367.SGD","IE00B031HY20.USD","IE00B543WZ88.USD","LU1960683339.HKD","LU1328277881.USD","BK1589","LU2097828714.EUR","LU1226287792.SGD","LU1152091168.USD","LU0067412154.USD","LU1951186391.HKD","SG9999004220.SGD","BK1161","BK1574","LU2242644610.SGD","IE00B5MMRT66.SGD","BK1593","01801","VXUS","IE00BZ08YT58.USD","BK1191","LU0501845795.SGD","LU1226288253.USD","LU1969619763.USD","HK0000165453.HKD","LU0314109678.HKD","LU1008478684.HKD","LU0072913022.USD","LU2039709279.SGD","01093","LU1993786604.SGD","BK1583","159992","01177","LU1813983027.USD","LU2488822045.USD","BK1515","LU2097828631.EUR","BK4588","LU0140636845.USD","LU0455707207.USD","LU0502904849.HKD","01530","LU2097828557.USD","06978","LU2328871848.SGD","LU1226287875.USD","IE0008369823.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641171097","title":"三生制药遭汇添富基金减持216.2万股 每股作价约17.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641171097","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641171097?lang=zh_cn&edition=full","pubTime":"2026-06-08 07:50","pubTimestamp":1780876200,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，6月2日，汇添富基金减持三生制药（01530）216.2万股，每股作价17.1455港元，总金额约为3706.86万港元。减持后最新持股数目约为1.78亿股，最新持股比例为6.99%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-08/doc-iniarzha4033964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HK0000165453.HKD","BK1583","BK1593","EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143691","title":"汇添富基金减持三生制药(01530)216.2万股 每股作价约17.15港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641143691?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:49","pubTimestamp":1780663754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月2日，汇添富基金减持三生制药(01530)216.2万股，每股作价17.1455港元，总金额约为3706.86万港元。减持后最新持股数目约为1.78亿股，最新持股比例为6.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","HK0000165453.HKD","BK1161","EWH","BK1583","BK1593"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0105},{"period":"1month","weight":-0.1205},{"period":"3month","weight":-0.3303},{"period":"6month","weight":-0.3794},{"period":"1year","weight":-0.2773},{"period":"ytd","weight":-0.3358}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0985},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1062},{"period":"1year","weight":-0.0571},{"period":"ytd","weight":-0.0996}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080954},{"month":6,"riseRate":0.727273,"avgChangeRate":0.021265},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}